Special BME Seminar
Monday, August 8, 2016
Speaker: Stephen Henry, Professor of Biotech Innovation, Centre for Kode Technology Innovation, Auckland University of Technology, Auckland, New Zealand.
Kode™ Technology is a multi-functional nanotechnology paint that can modify virtually any biological surface in less than 30 minutes and any non-biological surface in a few seconds. It is the easiest, fastest, most versatile and controllable method for temporary modification of any surface.
If your research or product involves the use of cells, viruses, organisms, bacteria, liposomes, nanoparticles, magnetic beads, solid surfaces or immunoassays then Kode biosurface modification technology can probably improve and accelerate your R&D outcomes and enhance your product.
Kode constructs can modify almost any biological or non-biological surface with characterized bioactives (including glycans, peptides, proteins, labels, fluorophores, anti-microbials, enzyme-substrates, chelators, etc), within a few minutes, and without affecting cell/virion/organisms vitality and functionality. Kode™ constructs can also modify solid surfaces including papers, nanofibres, filter membranes, plastic, rubbers, glass and metal in a just few seconds, with a water-resistant bioactive coating.
Additionally KODE™ technology can allow you to real-time image, immobilize, and separate modified cells / virions both in vitro and/or in vivo. It can also improve solubility, enable in vivo targeting, cause antigen masking, enhance or suppress bioactivity, improve in vivo half life, modify surface charge, improve functionality and visibility, neutralize antibodies and toxins, and inhibit infection (viral and microbial) and much more.
Kode™ Technology is a proven platform with hundreds of construct variations, 29 peer-reviewed journal articles, > 180 patents, several validated diagnostics products in the market, and now several therapeutic licensees with products in clinical evaluation, including seversl products for oncotherapy. Kode™ Technology is the active pharmaceutical ingredient in the Agalimmune oncotherapy Alphaject™ product due to enter clinical trails in 2016 (https://www.youtube.com/watch?v=otTnV8P6W4M).